We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...

ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...

That's where CRISPR Therapeutics falls short. The company's approved product, Casgevy, is an ex vivo gene editing treatment.

From the first approved CRISPR treatment to AI designing its own computer chips, check out this week's awesome tech stories ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...